Insulin Discontinuation Tension; FDA OKs Osteopenia Belt; Limited Mounjaro Supply

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, 番茄社区 January 30, 2024

Endo Break over a computer rendering of a man with illustrated body organs.

Type 1 diabetes patients are upset over the looming discontinuation of Novo Nordisk's . (USA Today)

Mid-life women with like arsenic, cadmium, and mercury may produce fewer eggs. (Journal of Clinical Endocrinology & Metabolism)

The FDA cleared as the first non-pharmacological device-based prescription treatment for postmenopausal women with osteopenia, the company announced.

While of a diabetes diagnosis was linked with remission, people seldom kept the weight off long-term. (PLOS Medicine)

The 12.5-mg dose of the type 2 diabetes drug tirzepatide (Mounjaro) throughout February due to increased demand. Other doses will still be available. (Reuters)

Shortages affecting access to GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic, Wegovy) have , the WHO warned.

Under a new policy, the Defense Department will to service members in any relationship status. (Military Times)

Meanwhile in New Jersey, will be expanded to now include LGBTQ+ individuals. (CBS News)

More recent drug developments and approvals are finally . (Time)

Beginning in April, will end state employees' coverage of semaglutide and other pricey drugs for weight loss. (New York Times)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she鈥檚 worked at the company since 2015.